MPI 674

Drug Profile

MPI 674

Alternative Names: Femathina; MPI 674

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator Mount Sinai Hospital (Toronto); Wayne State University
  • Developer Meditrina Pharmaceuticals
  • Class Antineoplastics; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Menstruation disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Feb 2008 Meditrina Pharmaceuticals has completed a global licensing agreement with AstraZeneca for aromatase inhibitors
  • 12 Apr 2007 Phase-II clinical trials in Menstruation disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top